Karen Seago, NP
Adult Health · Pearl, MSNPI 1164664348
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 160 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,155 and has fallen 52.7% since, to $546 in 2024.
Across 160 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$586
- AstraZeneca$493
- GSK$363
- Novo Nordisk$338
- Abbott$155
- Inspire Medical Systems, Inc.$149
- plus $908 from 22 others
What the payments were for
- Food & beverage$2,991100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $586 |
| AstraZeneca | 24 | $493 |
| GSK | 20 | $363 |
| Novo Nordisk | 25 | $338 |
| Abbott | 8 | $155 |
| Inspire Medical Systems, Inc. | 2 | $149 |
| Lilly USA, LLC | 9 | $127 |
| Boehringer Ingelheim | 8 | $122 |
| Pfizer | 7 | $112 |
| Merck | 5 | $90 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| Novartis | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Astellas Pharma US Inc | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Dexcom, Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $25 |
| Genentech USA, Inc. | 2 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Medtronic | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Mylan Specialty L.p. | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,991 in reported general payments places this provider in the 80th percentile of 93 adult health providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 13 | $178,496 |
| OzempicSemaglutide | 54 | $62,742 |
| JardianceEmpagliflozin | 31 | $29,325 |
| EliquisApixaban | 36 | $22,752 |
| FarxigaDapagliflozin Propanediol | 30 | $18,858 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $17,997 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $13,538 |
| LinzessLinaclotide | 14 | $10,993 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $6,364 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $2,439 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,898 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $1,611 |
| Omeprazole | 94 | $1,238 |
| Gabapentin | 81 | $1,163 |
| Valsartan | 53 | $1,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $25 | $178,49613 claims |
| Novo NordiskOzempic | $338 | $62,74254 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $493 | $36,85550 claims |
| Boehringer IngelheimJardiance | $122 | $29,32531 claims |
| PfizerEliquis | $112 | $22,75236 claims |
| GSKTrelegy Ellipta | $363 | $13,53819 claims |
| AbbVieLinzess | $586 | $10,99314 claims |
| MerckJanumet | $90 | $6,36411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 93 adult health providers in Mississippi.
Other adult health in Pearl
- Amanda GreeneRidgeland$108K
- Rhonda HickmanTupelo$15K
- Angela SlaterFlorence$14K
- Jennifer Delaney-DavisOcean Springs$9K
- Traci EvansGulfport$8K
- Casey AdamsGulfport$8K
- Keila BrownJackson$7K
- Brandi JohnstonJackson$7K
- Elizabeth WhiteHattiesburg$6K
- Jessica JonesHattiesburg$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.